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A 77-year-old Japanese man with bronchial asthma was treated with dupilumab. Dupilumab treatment was discontinued at the
patient’s request after two injections separated by a 2-week interval. +e blood eosinophil count was elevated, and an esoph-
agogastroduodenoscopy performed 3 months after dupilumab treatment revealed gastric ulcers; subsequently, eosinophilic
gastritis was diagnosed from biopsy examinations. +e gastric lesions were resolved by steroid administration. +is case report
underscores that eosinophil-associated gastrointestinal diseases should be considered in the differential diagnosis of gastric lesions
occurring in patients who were treated with dupilumab.
1. Introduction
Dupilumab, a human monoclonal antibody against inter-
leukin-4 (IL-4) and IL-13, is a subcutaneous injectable
prescription medicine used for the treatment of asthma and
atopic dermatitis [1, 2]. IL-4 and IL-13 initiate type 2 helper
T-cell (+2) mediated inflammatory processes, such as
immunoglobulin E (IgE) production, smooth muscle con-
traction, mucus production, and innate cell recruitment to
sites of inflammation, leading to allergic diseases [3]. As
dupilumab inhibits both IL-4 and IL-13 signaling, it has
beneficial effects in patients with asthma and atopic der-
matitis. +e efficacy, safety, and tolerability of dupilumab
have been investigated and confirmed in clinical trials [4, 5].
However, a higher frequency of eosinophilia in dupilumab-
treated patients has been reported both in clinical studies
[6, 7] and a real-world study [8].
Herein, we have reported the case of a patient with
asthma who developed eosinophilic gastritis after the ad-
ministration of dupilumab, with a focus on the possible
pathogenesis of eosinophil infiltration in the stomach.
2. Case Presentation
A 77-year-old Japanese man had visited a hospital with
respiratory distress, cough, and sputum. +e patient had
hyperlipidemia, hypertension, atrophic rhinitis, duodenal
ulcers, hyperuricemia, prostatic hypertrophy, and overactive
bladder, for which he had been taking pravastatin, cil-
nidipine, trichlormethiazide, lansoprazole, febuxostat, silo-
dosin, mirabegron, and a probiotic Lactobacillus
preparation. He was a social drinker and an ex-smoker who
smoked 30 cigarettes/day for 13 years. He had received
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Helicobacter pylori eradication treatment at 68 years of age.
Although the patient had a history of paranasal sinusitis and
occasionally suffered from a cough, he had not previously
been diagnosed with bronchial asthma.
His respiratory distress, cough, and sputum were im-
proved by the temporary administration of formoterol inhaler
and antibiotics. However, his symptoms reemerged after 3
months, and he visited a clinic. At that time, lung auscultation
revealed a wheeze in both the lungs. His oxygen saturation
was 89%–91%, his forced expiratory volume percentage in
one second was 76.9%, his peak expiratory flow rate was
22.5%, and his exhaled nitric oxide level was 29–31 ppb. +e
laboratory tests showed increased values for C-reactive
protein (1.53mg/dL) and immunoglobulin E (740 IU/mL),
whereas the number of white blood cells was within the
normal range (6,900 μL). Radioallergosorbent tests were
broadly positive for multiple allergens, such as house dust,
mites, pollens, candida, and wheat. Fluticasone, formoterol,
montelukast, and azithromycin were administered in addition
to intravenous methylprednisolone. Although his medication
was changed to vilanterol, fluticasone, and montelukast, his
respiratory distress, cough, and sputum production were not
completely resolved.+us, dupilumab was administered twice
separated by a 2-week interval. However, dupilumab treat-
ment was discontinued at the patient’s request because his
symptoms were unchanged. Although his eosinophil count
was within the normal range before the administration of
dupilumab, it varied from 152 to 860 μL after dupilumab
injections were initiated.+e patient was subsequently treated
with montelukast, bilastine, and zinc acetate.
+e patient underwent an esophagogastroduodenoscopy
3 months after the dupilumab treatment for annual screening
purposes. Esophagogastroduodenoscopy revealed gastric ul-
cers in the lesser curvature of the cardia (Figure 1(a)) and in
the posterior wall of the gastric body (Figure 1(b)). Whitish
mucosa was also observed in the lesser curvature of the gastric
body (Figure 1(c)). Although the patient had undergone
annual esophagogastroduodenoscopy for 9 years, gastric ul-
cers or whitish mucosa had not previously been identified.
Biopsy of the gastric ulcers revealed more than 100 eosino-
phils per high-power field, which were infiltrating into the
lamina propria and even the epithelium of the gastric mucosa
(Figure 2); no neoplastic cells were noted. Consequently, a
diagnosis of eosinophilic gastritis was made. +e laboratory
tests showed slightly increased values for C-reactive protein
(0.33mg/dL) and immunoglobulin E (366 IU/mL), whereas
white blood cells (6,900 μL) and eosinophils (5.3%) were
within the normal ranges. Computed tomography scanning
showed no remarkable changes in the gastrointestinal tract.
Consequently, 30mg prednisone was administered to treat
eosinophilic gastritis. Esophagogastroduodenoscopy per-
formed 4 weeks after prednisone administration revealed the
resolution of gastric ulcers (Figure 3). No eosinophils were
identified in the biopsied specimens.
3. Discussion
Several randomized, placebo-controlled phase 3 trials
revealed that dupilumab was effective for moderate-to-
severe atopic dermatitis [9–11]. Alexis et al. performed post
hoc analysis from three phase 3 trials assessing the efficacy
and safety of dupilumab vs placebo and identified that se-
rious adverse events occurredmore frequently in the placebo
groups [11]. However, a real-life study in a French multi-
center adult cohort revealed a higher frequency of eosino-
philia and conjunctivitis in patients with atopic dermatitis
treated with dupilumab, compared with clinical trials [12].
Placebo-controlled phase 3 trials showed the efficacy of
dupilumab for patients with moderate-to-severe or severe
asthma [6, 7, 13]. In one phase 3 trial involving 1,902 pa-
tients with uncontrolled asthma [7], 52/1,264 patients in the
dupilumab-treated group (4.1%) had eosinophilia, which
was associated with symptoms such as the deterioration of
chronic eosinophilic pneumonia and hypereosinophilia in
four patients. Meanwhile, eosinophilia was observed in 4/
638 patients in the placebo group (0.6%). Another phase 3
trial showed that transient blood eosinophilia was more
frequently observed in the dupilumab group (14/103 pa-
tients, 13.6%) than in the placebo group (1/107 patients,
0.9%).+ese results indicated that dupilumab treatment may
increase the blood eosinophil count in some patients with
atopic dermatitis and/or asthma. As dupilumab is consid-
ered to inhibit the migration of eosinophils into tissues by
blocking IL-4 and IL-13 signaling, it may transiently increase
circulating blood eosinophil counts [7, 14]. Another possible
mechanism of eosinophilia observed in clinical trials was the
withdrawal of glucocorticoids in dupilumab-treated pa-
tients, which caused the elevation of blood eosinophils [6, 7].
Other adverse events reported in association with
dupilumab included nasopharyngitis, bronchitis, sinusitis
[15], injection-site reactions [6], headache [16], skin infec-
tions, cutaneous psoriatic lesions [17], alopecia [18, 19], and
chronic eosinophilic pneumonia [20]. To the best of our
knowledge, the development of gastrointestinal diseases in
association with dupilumab use has not been reported
previously. +us, this report is the first to describe a patient
with eosinophilic gastritis that occurred after the use of
dupilumab.
In the present patient, dupilumab was administered
twice separated by a 2-week interval for the treatment of
asthma, and dupilumab treatment was discontinued
thereafter. Esophagogastroduodenoscopy performed 3
months after dupilumab treatment revealed eosinophilic
gastritis. +ere are several hypotheses regarding the oc-
currence of eosinophil infiltration in the present patient’s
stomach. First, the migration of eosinophil into organs was
blocked by dupilumab administration, and the chemotaxis
behavior may be altered when the migration was resumed
after the withdrawal of dupilumab, resulting in stomach-
predominant infiltration of eosinophils. Second, the stom-
ach may escape the chemotaxis-sparing effect of dupilumab,
and eosinophils converged in the gastric mucosa. +ird, the
patient was hyperallergic, which caused both asthma and
eosinophilic gastritis. Eosinophilic gastroenteritis is fre-
quently found in patients with atopic conditions [21].
+erefore, eosinophilic gastritis might occur coincidentally,
independent of dupilumab treatment. However, these hy-
potheses are speculative and not substantiated by any
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supporting facts. Because this report includes only one
patient with such a case, further investigation is required to
clarify the relationship between eosinophilic gastritis and
dupilumab use.
Menzella et al. reported a patient with chronic eosino-
philic pneumonia that developed after the tenth injection of
dupilumab [20]. Although a great improvement in asthma
control was obtained, the patient manifested eosinophilia,
fever, and bilateral pulmonary thickening. +e authors
described a progressive increase in blood eosinophil count
after dupilumab injections were started, followed by the
onset of chronic eosinophilic pneumonia. In the present
patient, blood eosinophil count was also elevated after the
administration of dupilumab. +ese results suggested that
end-organ manifestations of eosinophilia may occur, re-
gardless of whether the patient is receiving dupilumab
treatment or treatment has been discontinued. It was also
noteworthy that the patient had no gastrointestinal
(a) (b) (c)
Figure 3: Esophagogastroduodenoscopy images. Endoscopy performed 4 weeks after prednisone administration revealed the resolution of
gastric ulcers. No eosinophils were identified in the biopsied specimens.
(a) (b) (c)
Figure 1: Esophagogastroduodenoscopy images. Esophagogastroduodenoscopy performed 3 months after dupilumab treatment revealed
gastric ulcers in the lesser curvature of the cardia (a) and posterior wall of the gastric body (b). Whitish mucosa was also noted in the lesser
curvature of the gastric body (c).
(a) (b)
Figure 2: Pathology images. Biopsy from the gastric ulcers showed the infiltration of eosinophils (a× 4; b× 40).
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symptoms despite havingmultiple stomach ulcers secondary
to eosinophil infiltration. Although screening esoph-
agogastroduodenoscopy after administration of dupilumab
may reveal asymptomatic gastrointestinal involve-
ment—particularly in patients with eosinophilia—this
concept needs further investigation.We hope this report will
raise awareness of the potential for eosinophil-associated
gastrointestinal disease following dupilumab use.
In conclusion, we encountered a patient with asthma
who developed eosinophilic gastritis 3 months after dupi-
lumab use. +is case supports the consideration of eosin-
ophilic gastritis in the differential diagnosis of gastric lesions
emerging in patients who were treated with dupilumab.
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